Novo Nordisk receives a positive opinion from the CHMP for a label update of Wegovy to reflect reduced heart failure symptoms ...

Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for an update of Novo Nordisk A/S’ (NYSE ...

The European Medicines Agency’s (EMA) advisory committee the CHMP has adopted a positive opinion for a label update of Danish ...

Novo Nordisk’s obesity drug Wegovy is now recommended by EU regulatory authorities for obesity-related heart conditions.

The company noted that Wegovy is the first obesity medication to receive a positive opinion recommending a label update that reflects reduced symptoms and improved physical limitations and exercise ...

A new study found that people taking Wegovy during the pandemic were 33 percent less likely to die of COVID-19.

A slow-release form of semaglutide could allow people who use Wegovy or Ozempic to get shots once a month, instead of the ...

Researchers found that patients with obesity had an average weight loss of 12.9% with semaglutide vs 5.6% with liraglutide ...

The European Medicines Agency backed the use of Novo Nordisk's popular drug Wegovy to help ease heart failure in people with ...

U.S. telehealth company Hims & Hers Health on Wednesday said it will sell compounded versions of Novo Nordisk's popular ...

A slow-release form of semaglutide could allow people who use Wegovy or Ozempic to get shots once a month, instead of ...